TiumBio Co., Ltd. (KOSDAQ:321550)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,190.00
-30.00 (-0.93%)
Feb 21, 2025, 9:00 AM KST
-59.21%
Market Cap 85.21B
Revenue (ttm) 7.67B
Net Income (ttm) -20.35B
Shares Out 26.71M
EPS (ttm) -799.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 157,308
Average Volume 73,506
Open 3,200.00
Previous Close 3,220.00
Day's Range 3,000.00 - 3,240.00
52-Week Range 3,000.00 - 8,980.00
Beta 0.70
RSI 27.98
Earnings Date Mar 21, 2025

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. TiumBio Co., Ltd. was founded in 2016 and is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 321550
Full Company Profile

Financial Performance

In 2023, TiumBio's revenue was 4.90 billion, a decrease of -46.27% compared to the previous year's 9.12 billion. Losses were -17.91 billion, -40.00% less than in 2022.

Financial Statements

News

There is no news available yet.